

Fabrizio Vinante

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4241845/publications.pdf>

Version: 2024-02-01

65
papers

3,100
citations

293460

24
h-index

175968

55
g-index

65
all docs

65
docs citations

65
times ranked

4732
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of Protein Tyrosine Phosphatase Receptor Type β^3 Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells. <i>Journal of Immunology</i> , 2021, 207, 671-684.	0.4	4
2	The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment. <i>Cancers</i> , 2020, 12, 3757.	1.7	13
3	Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment. <i>Leukemia and Lymphoma</i> , 2019, 60, 3395-3405.	0.6	18
4	West Nile virus encephalitis in haematological setting: report of two cases and brief review of the literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019033.	0.5	7
5	BID and the β -bisabolol-triggered cell death program: converging on mitochondria and lysosomes. <i>Cell Death and Disease</i> , 2019, 10, 889.	2.7	15
6	Monocyte-to-macrophage switch reversibly impaired by Ibrutinib. <i>Oncotarget</i> , 2019, 10, 1943-1956.	0.8	9
7	CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase. <i>Oncotarget</i> , 2018, 9, 35123-35140.	0.8	23
8	Efficient lysis of B-chronic lymphocytic leukemia cells by the plant-derived sesquiterpene alcohol β -bisabolol, a dual proapoptotic and antiautophagic agent. <i>Oncotarget</i> , 2018, 9, 25877-25890.	0.8	6
9	A single amino acid substitution in CXCL12 confers functional selectivity at the beta-arrestin level. <i>Oncotarget</i> , 2018, 9, 28830-28841.	0.8	1
10	High prevalence of antibodies reacting to mimotopes of Simian virus 40 large T antigen, the oncoprotein, in serum samples of patients affected by non-Hodgkin lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1189-1198.	2.0	4
11	Endothelin β_1 receptor blockade as new possible therapeutic approach in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 781-793.	1.2	21
12	Morphological and Functional Changes in the Peritumoral Adipose Tissue of Colorectal Cancer Patients. <i>Obesity</i> , 2017, 25, S87-S94.	1.5	27
13	Flow cytometry analysis of receptor internalization/shedding. <i>Cytometry Part B - Clinical Cytometry</i> , 2017, 92, 291-298.	0.7	6
14	The antineoplastic agent β -bisabolol promotes cell death by inducing pores in mitochondria and lysosomes. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2016, 21, 917-927.	2.2	18
15	Immunologic evidence of a strong association between non-Hodgkin lymphoma and simian virus 40. <i>Cancer</i> , 2015, 121, 2618-2626.	2.0	22
16	Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome. <i>Clinical Cancer Research</i> , 2015, 21, 5164-5172.	3.2	33
17	JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 34245-34257.	0.8	21
18	Hairy cell leukemia in kidney transplantation: lesson from a rare disorder. <i>Experimental Hematology and Oncology</i> , 2013, 2, 22.	2.0	1

#	ARTICLE	IF	CITATIONS
19	Heparin-Binding Epidermal Growth Factor-like Growth Factor/Diphtheria Toxin Receptor in Normal and Neoplastic Hematopoiesis. <i>Toxins</i> , 2013, 5, 1180-1201.	1.5	32
20	CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin. <i>PLoS ONE</i> , 2012, 7, e34432.	1.1	10
21	Î±-bisabolol Is an Effective Proapoptotic Agent against BCR-ABL+ Cells in Synergism with Imatinib and Nilotinib. <i>PLoS ONE</i> , 2012, 7, e46674.	1.1	16
22	Pro-apoptotic activity of Î±-bisabolol in preclinical models of primary human acute leukemia cells. <i>Journal of Translational Medicine</i> , 2011, 9, 45.	1.8	56
23	The Sesquiterpene Oil Î±-Bisabolol Induces Apoptosis of B-Chronic Lymphocytic Leukemia Primary Cells. <i>Blood</i> , 2011, 118, 1319-1319.	0.6	0
24	Protein Tyrosine Phosphatase Receptor Type Î³ Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia. <i>Cancer Research</i> , 2010, 70, 8896-8906.	0.4	46
25	Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. <i>Molecular Cancer</i> , 2010, 9, 273.	7.9	99
26	Comparative Analysis of Normal versus CLL B-Lymphocytes Reveals Patient-Specific Variability in Signaling Mechanisms Controlling LFA-1 Activation by Chemokines. <i>Cancer Research</i> , 2009, 69, 9281-9290.	0.4	36
27	Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-Î±B and JNK/AP-1 pathways. <i>Haematologica</i> , 2008, 93, 524-532.	1.7	51
28	Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. <i>Haematologica</i> , 2007, 92, 264-266.	1.7	51
29	Role for Interferon-Î³ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells. <i>Stem Cells</i> , 2006, 24, 386-398.	1.4	1,226
30	HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. <i>Blood</i> , 2005, 106, 59-66.	0.6	210
31	Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. <i>Haematologica</i> , 2003, 88, 1229-37.	1.7	25
32	CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540. <i>Blood</i> , 2002, 99, 52-60.	0.6	25
33	Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases. <i>Genes Chromosomes and Cancer</i> , 2002, 33, 93-97.	1.5	92
34	Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases. <i>Trends in Immunology</i> , 2001, 22, 72-77.	2.9	76
35	Naturally-occurring anti-G-CSF antibodies produced by human cord blood B-cell lines infected with Epstein-Barr virus. <i>The Hematology Journal</i> , 2001, 2, 161-171.	2.0	2
36	Antibodies Binding Granulocyte Macrophage Colony Stimulating Factor Produced by Cord Blood-Derived B Cell Lines Immortalized by Epstein-Barr Virus in Vitro. <i>Cellular Immunology</i> , 2000, 204, 114-127.	1.4	11

#	ARTICLE	IF	CITATIONS
37	Granulocyte-Macrophage Colony-Stimulating Factor Induces Expression of Heparin-Binding Epidermal Growth Factor-like Growth Factor/Diphtheria Toxin Receptor and Sensitivity to Diphtheria Toxin in Human Neutrophils. <i>Blood</i> , 1999, 94, 3169-3177.	0.6	28
38	Heparin-Binding Epidermal Growth Factor-like Growth Factor/Diphtheria Toxin Receptor Expression by Acute Myeloid Leukemia Cells. <i>Blood</i> , 1999, 93, 1715-1723.	0.6	22
39	Interleukin-8 in Acute Myeloid Leukemia. <i>Blood</i> , 1999, 93, 1437-1437.	0.6	3
40	Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration. <i>Clinical and Experimental Immunology</i> , 1999, 117, 291-297.	1.1	52
41	Lymphocyte membrane antigen expression and intracellular cytokine patterns in an asymptomatic patient with persistently high serum levels of IgE. <i>Annals of Allergy, Asthma and Immunology</i> , 1999, 83, 144-148.	0.5	3
42	Granulocyte-Macrophage Colony-Stimulating Factor Induces Expression of Heparin-Binding Epidermal Growth Factor-like Growth Factor/Diphtheria Toxin Receptor and Sensitivity to Diphtheria Toxin in Human Neutrophils. <i>Blood</i> , 1999, 94, 3169-3177.	0.6	1
43	Interleukin-8 in Acute Myeloid Leukemia. <i>Blood</i> , 1999, 93, 1437-1437.	0.6	1
44	Heparin-Binding Epidermal Growth Factor-like Growth Factor/Diphtheria Toxin Receptor Expression by Acute Myeloid Leukemia Cells. <i>Blood</i> , 1999, 93, 1715-1723.	0.6	1
45	Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome. <i>British Journal of Haematology</i> , 1998, 102, 1025-1034.	1.2	38
46	Circulating levels of soluble CD23 reflect clinical and biological features of leukemic B-cell chronic lymphoproliferative disorders. <i>International Journal of Clinical and Laboratory Research</i> , 1995, 25, 189-194.	1.0	5
47	High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. <i>Aids</i> , 1994, 8, 741-746.	1.0	118
48	Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome. <i>Cancer</i> , 1993, 72, 201-206.	2.0	38
49	Soluble interleukin-2 receptor in hairy-cell leukemia: a reliable marker of disease. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 34-37.	1.0	11
50	High Serum Levels of Soluble Interleukin-2 Receptor and Absence of Detectable Levels of Soluble CD30 Molecule: A Specific Diagnostic Combination for Hairy Cell Leukemia. <i>Leukemia and Lymphoma</i> , 1992, 6, 385-388.	0.6	2
51	Determinants of HIV disease progression. <i>Lancet</i> , The, 1992, 339, 130.	6.3	2
52	Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro. <i>Cellular Immunology</i> , 1992, 141, 253-259.	1.4	12
53	Shedding of the soluble form of the CD8 complex by CD8 +/HLA-DR + cells in HIV-1-infected patients. <i>Aids</i> , 1991, 5, 813-820.	1.0	15
54	Serum levels of soluble interleukin-2 receptors in acute and chronic viral hepatitis. <i>Digestive Diseases and Sciences</i> , 1989, 34, 1559-1563.	1.1	23

#	ARTICLE	IF	CITATIONS
55	Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission. <i>Cancer</i> , 1989, 64, 667-672.	2.0	16
56	Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lymphoproliferative disorders of T-lymphocytes. <i>Cancer</i> , 1989, 64, 2019-2023.	2.0	15
57	Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 1577-1581.	0.9	5
58	Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. <i>Clinical Immunology and Immunopathology</i> , 1989, 50, 146-153.	2.1	27
59	Increased Levels of Soluble Interleukin-2 Receptor in Non-Hodgkin's Lymphomas: Relationship with Clinical, Histologic, and Phenotypic Features. <i>American Journal of Clinical Pathology</i> , 1989, 92, 186-191.	0.4	48
60	Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. <i>Journal of Clinical Immunology</i> , 1988, 8, 447-452.	2.0	71
61	Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. <i>British Journal of Cancer</i> , 1987, 55, 427-428.	2.9	106
62	Immunologic abnormalities in angioimmunoblastic lymphadenopathy. <i>Cancer</i> , 1987, 60, 2412-2418.	2.0	25
63	Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: Evaluation of cytotoxic events. <i>Leukemia Research</i> , 1987, 11, 843-847.	0.4	13
64	Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 1985, 56, 328-332.	2.0	61
65	Gram-negative septicemia in patients with hematologic malignancies. <i>European Journal of Cancer & Clinical Oncology</i> , 1984, 20, 327-331.	0.9	25